Se connecter

Bibliographies thématiques / ApolipoproteinA-I Milano / Articles de revues

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : ApolipoproteinA-I Milano.

Articles de revues sur le sujet « ApolipoproteinA-I Milano »

Auteur : Grafiati

Publié le 14 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 27 meilleurs articles de revues pour votre recherche sur le sujet « ApolipoproteinA-I Milano ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Shah, P. K., J. Nilsson, S. Kaul, et al. "Inhibition of aortic atherosclerosis in apolipoprotein E-deficient mice by recombinant apolipoprotein A-I Milano." Journal of the American College of Cardiology 31 (February 1998): 390. http://dx.doi.org/10.1016/s0735-1097(98)80043-0.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Shah, P. "Inhibition of Aortic Atherosclerosis in Apolipoprotein E-deficient Mice by Recombinant Apolipoprotein A-I Milano." Journal of the American College of Cardiology 31, no. 2 (1998): 390A. http://dx.doi.org/10.1016/s0735-1097(97)85397-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Bhat, Shaila, Mary G. Sorci-Thomas, Laura Calabresi, Michael P. Samuel, and Michael J. Thomas. "Conformation of Dimeric Apolipoprotein A-I Milano on Recombinant Lipoprotein Particles." Biochemistry 49, no. 25 (2010): 5213–24. http://dx.doi.org/10.1021/bi1003734.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Klon, Anthony E., Martin K. Jones, Jere P. Segrest, and Stephen C. Harvey. "Molecular Belt Models for the Apolipoprotein A-I Paris and Milano Mutations." Biophysical Journal 79, no. 3 (2000): 1679–85. http://dx.doi.org/10.1016/s0006-3495(00)76417-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Bielicki, John K., Mark R. McCall, Lori J. Stoltzfus, et al. "Evidence That Apolipoprotein A-I Milano Has Reduced Capacity, Compared With Wild-Type Apolipoprotein A-I, to Recruit Membrane Cholesterol." Arteriosclerosis, Thrombosis, and Vascular Biology 17, no. 9 (1997): 1637–43. http://dx.doi.org/10.1161/01.atv.17.9.1637.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Coin, B. D., P. K. Shah, J. Yano, M. D. Molloy, B. Cercek, and S. Kaul. "Reversal of impaired endothelium-dependent vasodilatation in apolipoprotein E-deficient mice by recombinant apolipoprotein A-I Milano." Journal of the American College of Cardiology 31 (1998): 60–61. http://dx.doi.org/10.1016/s0735-1097(98)80909-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Bielicki, J. K., T. M. Forte, M. R. McCall, et al. "High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice." Journal of Lipid Research 38, no. 11 (1997): 2314–21. http://dx.doi.org/10.1016/s0022-2275(20)34945-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Coin, B. D., P. K. Shah, J. Yano, M. D. Molloy, B. Cercek, and S. Kaul. "Recombinant apolipoprotein A-I Millano protects against lysophosphatidylcholine-induced endothelial dysfunction." Journal of the American College of Cardiology 31 (1998): 148. http://dx.doi.org/10.1016/s0735-1097(98)81288-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Alexander, Eric T., Masafumi Tanaka, Momoe Kono, Hiroyuki Saito, Daniel J. Rader, and Michael C. Phillips. "Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I." Journal of Lipid Research 50, no. 7 (2009): 1409–19. http://dx.doi.org/10.1194/jlr.m800578-jlr200.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Ameli, S., A. Hultgardh-Nilsson, B. Cercek, et al. "Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits." Circulation 90, no. 4 (1994): 1935–41. http://dx.doi.org/10.1161/01.cir.90.4.1935.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

Ma, Cheng-I. J., Jennifer A. Beckstead, Airlia Thompson, et al. "Tweaking the cholesterol efflux capacity of reconstituted HDL." Biochemistry and Cell Biology 90, no. 5 (2012): 636–45. http://dx.doi.org/10.1139/o2012-015.

Texte intégral

Résumé :

Mechanisms to increase plasma high-density lipoprotein (HDL) or to promote egress of cholesterol from cholesterol-loaded cells (e.g., foam cells from atherosclerotic lesions) remain an important target to regress heart disease. Reconstituted HDL (rHDL) serves as a valuable vehicle to promote cellular cholesterol efflux in vitro and in vivo. rHDL were prepared with wild type apolipoprotein (apo) A-I and the rare variant, apoA-I Milano (M), and each apolipoprotein was reconstituted with phosphatidylcholine (PC) or sphingomyelin (SM). The four distinct rHDL generated were incubated with CHO cells

Styles APA, Harvard, Vancouver, ISO, etc.

12

Bruckert, Eric, Arnold von Eckardstein, Harald Funke, et al. "The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-I Milano." Atherosclerosis 128, no. 1 (1997): 121–28. http://dx.doi.org/10.1016/s0021-9150(96)05982-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

Wang, Lai, Behrooz G. Sharifi, Theresa Pan, Lei Song, Ada Yukht, and Prediman K. Shah. "Bone Marrow Transplantation Shows Superior Atheroprotective Effects of Gene Therapy With Apolipoprotein A-I Milano Compared With Wild-Type Apolipoprotein A-I in Hyperlipidemic Mice." Journal of the American College of Cardiology 48, no. 7 (2006): 1459–68. http://dx.doi.org/10.1016/j.jacc.2006.07.040.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

Nicholls, Stephen J., E. Murat Tuzcu, Ilke Sipahi, et al. "Relationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano." Journal of the American College of Cardiology 47, no. 5 (2006): 992–97. http://dx.doi.org/10.1016/j.jacc.2005.11.040.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Cimmino, Giovanni, Walter S. Speidl, Sammy Elmariah, et al. "RECOMBINANT APOLIPOPROTEIN A-I MILANO DECREASES LEAFLET INFLAMMATION AND CALCIFICATION IN EXPERIMENTAL MODELS OF AORTIC STENOSIS." Journal of the American College of Cardiology 55, no. 10 (2010): A152.E1426. http://dx.doi.org/10.1016/s0735-1097(10)61427-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

16

Rocco, Alessandro Guerini, Cristina Sensi, Elisabetta Gianazza, et al. "Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL." Journal of Molecular Graphics and Modelling 29, no. 3 (2010): 406–14. http://dx.doi.org/10.1016/j.jmgm.2010.08.002.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

17

Bekaert, ED, P. Alaupovic, CS Knight-Gibson, G. Franceschini, and CR Sirtori. "Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles." Journal of Lipid Research 34, no. 1 (1993): 111–23. http://dx.doi.org/10.1016/s0022-2275(20)41325-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

18

Guerini Rocco, A., L. Mollica, E. Gianazza, L. Calabresi, C. R. Sirtori, and I. Eberini. "Tu-W16:8 A structural model for apolipoprotein A-I Milano (A-IM) in its heterodimeric form with apolipoprotein A-II (A-II)." Atherosclerosis Supplements 7, no. 3 (2006): 154. http://dx.doi.org/10.1016/s1567-5688(06)80604-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

Speidl, W. S., G. Cimmino, B. Ibanez, et al. "Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model." European Heart Journal 31, no. 16 (2010): 2049–57. http://dx.doi.org/10.1093/eurheartj/ehq064.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Nicholls, Stephen J., Rishi Puri, Christie M. Ballantyne, et al. "Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial." JAMA Cardiology 3, no. 9 (2018): 806. http://dx.doi.org/10.1001/jamacardio.2018.2112.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Kaul, Sanjay, Vladimir Rukshin, Raul Santos, et al. "Intramural Delivery of Recombinant Apolipoprotein A-I Milano /Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries." Circulation 107, no. 20 (2003): 2551–54. http://dx.doi.org/10.1161/01.cir.0000074042.19447.b1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Gomaraschi, Monica, Damiano Baldassarre, Mauro Amato, et al. "Normal Vascular Function Despite Low Levels of High-Density Lipoprotein Cholesterol in Carriers of the Apolipoprotein A-I Milano Mutant." Circulation 116, no. 19 (2007): 2165–72. http://dx.doi.org/10.1161/circulationaha.107.705657.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

Chetty, Palaniappan Sevugan, Maki Ohshiro, Hiroyuki Saito, et al. "Effects of the Iowa and Milano Mutations on Apolipoprotein A-I Structure and Dynamics Determined by Hydrogen Exchange and Mass Spectrometry." Biochemistry 51, no. 44 (2012): 8993–9001. http://dx.doi.org/10.1021/bi300926j.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

Yan, Ying, Shulai Lu, Shaoyou Jia, Qingzhe Dong, Lei Wang, and Yunlong Wang. "Function of different proportions of apolipoprotein A-I cysteine mutants and apolipoprotein A-V on recombinant high-density lipoproteins in vitro." Bioscience Reports 39, no. 5 (2019). http://dx.doi.org/10.1042/bsr20190547.

Texte intégral

Résumé :

Abstract To explore the anti-atherosclerotic effects of recombinant high-density lipoproteins (rHDL) of apolipoprotein AI wild-type (apoA-Iwt), apolipoprotein AI Milano (apoA-IM), apolipoprotein AI (N74C) (apoA-I (N74C) )and apolipoprotein AV (apoA-V). We constructed rHDL liposomes (rHDLs), which included apoA-Iwt, apoA-IM, and apoA-I (N74C), followed by the synthesis of rHDLs, with the indicated ratios of apoA-Iwt, apoA-IM, apoA-I (N74C) and apoA-V. We investigated the anti-atherosclerotic effects by experiments including the DMPC clearance assay and experiments that assessed the in vitro ant

Styles APA, Harvard, Vancouver, ISO, etc.

25

Kalayci, Arzu, C. Michael Gibson, Paul M. Ridker, et al. "ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future." Current Atherosclerosis Reports, May 7, 2022. http://dx.doi.org/10.1007/s11883-022-01025-7.

Texte intégral

Résumé :

Abstract Purpose of Review The elevated adverse cardiovascular event rate among patients with low high-density lipoprotein cholesterol (HDL-C) formed the basis for the hypothesis that elevating HDL-C would reduce those events. Attempts to raise endogenous HDL-C levels, however, have consistently failed to show improvements in cardiovascular outcomes. However, steady-state HDL-C concentration does not reflect the function of this complex family of particles. Indeed, HDL functions correlate only weakly with serum HDL-C concentration. Thus, the field has pivoted from simply raising the quantity o

Styles APA, Harvard, Vancouver, ISO, etc.

26

Bellibas, S. Eralp, David Kallend, Alain Bobillier, Herman Kempen, and Peter L. Wijngaard. "Abstract 13324: Single Ascending Dose Pharmacokinetics and Pharmacodynamics of MDCO-216 (ApoA-I Milano/POPC) in Healthy Volunteers." Circulation 130, suppl_2 (2014). http://dx.doi.org/10.1161/circ.130.suppl_2.13324.

Texte intégral

Résumé :

Introduction: MDCO-216, a complex of dimeric recombinant apolipoprotein A-I Milano (apoA-I M) and a phospholipid (POPC), is currently under development to improve cardiovascular outcomes by reducing plaque burden in patients with atherosclerotic disease. An earlier version of MDCO-216 has been shown to reduce atherosclerotic plaque burden in animal models and in patients with ACS. The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of newly manufactured MDCO-216 first time in healthy volunteers. Methods: 24 healthy volunteers receiv

Styles APA, Harvard, Vancouver, ISO, etc.

27

Bellibas, S. Eralp, David Kallend, Alain Bobillier, Herman Kempen, and Peter L. Wijngaard. "Abstract 13357: MDCO-216 (ApoA-I Milano/POPC) Induces Reverse Cholesterol Transport in Stable Coronary Artery Disease Patients with a Dose Proportional Pharmacokinetics after Single Ascending Doses." Circulation 130, suppl_2 (2014). http://dx.doi.org/10.1161/circ.130.suppl_2.13357.

Texte intégral

Résumé :

Introduction: MDCO-216, a complex of dimeric recombinant apolipoprotein A-I Milano (apoA-I M) and a phospholipid (POPC), is currently under development to improve cardiovascular outcomes by reducing plaque burden in patients with atherosclerotic disease. An earlier version of MDCO-216 has been shown effective in animal models and in patients with ACS. The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD) and safety of MDCO-216, manufactured by an improved process, first time in stable coronary artery disease (CAD) patients. Methods: 24 patients with known sta

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!